Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos

Regulatory Affairs
Return to: PBR Home | Regulatory Affairs

Health Canada approves Forest Laboratories hypertension therapy

PBR Staff Writer Published 18 January 2013

Health Canada has issued a notice of compliance for Forest Laboratories Canada's hypertension therapy, Bystolic (nebivolol) tablets.

The company anticipates making the hypertension medication, that is to be administered once a day, available to patients across Canada in the second quarter of 2013.

Forest Laboratories corporate development and strategic planning senior vice president David Solomon said, "We are pleased that Health Canada has granted approval for BYSTOLIC. This is an important milestone for Forest, as it is the first product approved for our newly established Canadian subsidiary."

Nebivolol is a beta adrenergic receptor blocking agent which is metabolized by various routes such as glucuronidation and hydroxylation by CYP2D6.

Possible factors that allow Bystolic to act as antihypertensive agent include decreased heart rate, decreased myocardial contractility, diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers, suppression of renin activity and vasodilation and decreased peripheral vascular resistance.